These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 20541566)

  • 21. Diverse pattern of protease inhibitor resistance mutations in HIV-1 infected patients failing nelfinavir.
    Svedhem V; Lindkvist A; Bergroth T; Knut L; Sönnerborg A
    J Med Virol; 2005 Aug; 76(4):447-51. PubMed ID: 15977242
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Genotypic resistance profiles in antiretroviral-naive HIV-1 infections before and after initiation of first-line HAART: impact of polymorphism on resistance to therapy.
    Sukasem C; Churdboonchart V; Sukeepaisarncharoen W; Piroj W; Inwisai T; Tiensuwan M; Chantratita W
    Int J Antimicrob Agents; 2008 Mar; 31(3):277-81. PubMed ID: 18182278
    [TBL] [Abstract][Full Text] [Related]  

  • 23. HIV type-1 genotypic resistance profiles in vertically infected patients from Argentina reveal an association between K103N+L100I and L74V mutations.
    Aulicino PC; Rocco CA; Mecikovsky D; Bologna R; Mangano A; Sen L
    Antivir Ther; 2010; 15(4):641-50. PubMed ID: 20587857
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Subtype analysis and mutations to antiviral drugs in HIV-1-infected patients from Mozambique before initiation of antiretroviral therapy: results from the DREAM programme.
    Bellocchi MC; Forbici F; Palombi L; Gori C; Coelho E; Svicher V; D'Arrigo R; Emberti-Gialloreti L; Ceffa S; Erba F; Marazzi MC; Silberstein FC; Perno CF
    J Med Virol; 2005 Aug; 76(4):452-8. PubMed ID: 15977236
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Drug resistance mutations and newly recognized treatment-related substitutions in the HIV-1 protease gene: prevalence and associations with drug exposure and real or virtual phenotypic resistance to protease inhibitors in two clinical cohorts of antiretroviral experienced patients.
    Torti C; Quiros-Roldan E; Monno L; Patroni A; Saracino A; Angarano G; Tinelli C; Lo Caputo S; Tirelli V; Mazzotta F; Carosi G; ;
    J Med Virol; 2004 Sep; 74(1):29-33. PubMed ID: 15258965
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Selection of resistance in protease inhibitor-experienced, human immunodeficiency virus type 1-infected subjects failing lopinavir- and ritonavir-based therapy: mutation patterns and baseline correlates.
    Mo H; King MS; King K; Molla A; Brun S; Kempf DJ
    J Virol; 2005 Mar; 79(6):3329-38. PubMed ID: 15731227
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Genotypic resistance tests for the management of the HIV-infected patient with non-B viral isolates.
    Visco-Comandini U; Balotta C
    Scand J Infect Dis Suppl; 2003; 106():75-8. PubMed ID: 15000590
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prevalence of the K65R resistance reverse transcriptase mutation in different HIV-1 subtypes in Israel.
    Turner D; Shahar E; Katchman E; Kedem E; Matus N; Katzir M; Hassoun G; Pollack S; Kessner R; Wainberg MA; Avidor B
    J Med Virol; 2009 Sep; 81(9):1509-12. PubMed ID: 19626612
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Protease inhibition in African subtypes of HIV-1.
    Velázquez-Campoy A; Vega S; Fleming E; Bacha U; Sayed Y; Dirr HW; Freire E
    AIDS Rev; 2003; 5(3):165-71. PubMed ID: 14598565
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sustained appearance of drug resistance-associated mutations in HIV-1 CRF01_AE protease and reverse transcriptase derived from protease inhibitor-naive Thai patients.
    Jullaksorn D; Boonchawalit S; Uttiyoung J; Soonthornsata B; Yowang A; Krathong N; Chautrakul S; Ikuta K; Roobsoong A; Kanitvittaya S; Sawanpanyalert P; Kameoka M
    Southeast Asian J Trop Med Public Health; 2010 Mar; 41(2):347-57. PubMed ID: 20578518
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Genotypic and phenotypic evolution of HIV type-1 protease during in vitro sequential or concomitant combination of atazanavir and amprenavir.
    Cunyat F; Ruiz L; Marfil S; Puig T; Bofill M; Blanco J; Clotet B; Cabrera C
    Antivir Ther; 2010; 15(3):431-6. PubMed ID: 20516562
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A major role for a set of non-active site mutations in the development of HIV-1 protease drug resistance.
    Muzammil S; Ross P; Freire E
    Biochemistry; 2003 Jan; 42(3):631-8. PubMed ID: 12534275
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Polymorphism in HIV-1 non-subtype B protease and reverse transcriptase and its potential impact on drug susceptibility and drug resistance evolution.
    Kantor R; Katzenstein D
    AIDS Rev; 2003; 5(1):25-35. PubMed ID: 12875105
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The HIV-1 protease resistance mutation I50L is associated with resistance to atazanavir and susceptibility to other protease inhibitors in multiple mutational contexts.
    Sista P; Wasikowski B; Lecocq P; Pattery T; Bacheler L
    J Clin Virol; 2008 Aug; 42(4):405-8. PubMed ID: 18472298
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Natural polymorphisms in the human immunodeficiency virus type 2 protease can accelerate time to development of resistance to protease inhibitors.
    Ntemgwa M; Brenner BG; Oliveira M; Moisi D; Wainberg MA
    Antimicrob Agents Chemother; 2007 Feb; 51(2):604-10. PubMed ID: 17116674
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Novel human immunodeficiency virus type 1 protease mutations potentially involved in resistance to protease inhibitors.
    Svicher V; Ceccherini-Silberstein F; Erba F; Santoro M; Gori C; Bellocchi MC; Giannella S; Trotta MP; Monforte Ad; Antinori A; Perno CF
    Antimicrob Agents Chemother; 2005 May; 49(5):2015-25. PubMed ID: 15855527
    [TBL] [Abstract][Full Text] [Related]  

  • 37. TMC114, a novel human immunodeficiency virus type 1 protease inhibitor active against protease inhibitor-resistant viruses, including a broad range of clinical isolates.
    De Meyer S; Azijn H; Surleraux D; Jochmans D; Tahri A; Pauwels R; Wigerinck P; de Béthune MP
    Antimicrob Agents Chemother; 2005 Jun; 49(6):2314-21. PubMed ID: 15917527
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Non-cleavage site gag mutations in amprenavir-resistant human immunodeficiency virus type 1 (HIV-1) predispose HIV-1 to rapid acquisition of amprenavir resistance but delay development of resistance to other protease inhibitors.
    Aoki M; Venzon DJ; Koh Y; Aoki-Ogata H; Miyakawa T; Yoshimura K; Maeda K; Mitsuya H
    J Virol; 2009 Apr; 83(7):3059-68. PubMed ID: 19176623
    [TBL] [Abstract][Full Text] [Related]  

  • 39. GRL-02031, a novel nonpeptidic protease inhibitor (PI) containing a stereochemically defined fused cyclopentanyltetrahydrofuran potent against multi-PI-resistant human immunodeficiency virus type 1 in vitro.
    Koh Y; Das D; Leschenko S; Nakata H; Ogata-Aoki H; Amano M; Nakayama M; Ghosh AK; Mitsuya H
    Antimicrob Agents Chemother; 2009 Mar; 53(3):997-1006. PubMed ID: 18955518
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Protease sequences from HIV-1 group M subtypes A-H reveal distinct amino acid mutation patterns associated with protease resistance in protease inhibitor-naive individuals worldwide. HIV Variant Working Group.
    Pieniazek D; Rayfield M; Hu DJ; Nkengasong J; Wiktor SZ; Downing R; Biryahwaho B; Mastro T; Tanuri A; Soriano V; Lal R; Dondero T
    AIDS; 2000 Jul; 14(11):1489-95. PubMed ID: 10983635
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.